Publications by authors named "Cristina Suarez-Ferrer"
Objective: Our objective was to validate a previously published simple ultrasound (US) score for Crohn's disease (CD).
Methods: A total of 107 CD patients from 2 hospitals prospectively underwent both ileocolonoscopy (reference standard) and US as part of their clinical care. Endoscopic activity was assessed using the Simple Endoscopic Score for Crohn's Disease (SES-CD) and was also categorized as absent, mild (inflammation without ulcers), or severe (presence of ulceration).
Aims: The aim of the study is to evaluate the clinical and biochemical response of inflammatory bowel disease patients treated with vedolizumab, 16 weeks after transitioning from intravenous (iv) to subcutaneous (sc).
Methods: An observational, prospective, single-center cohort study was performed. Patients with inflammatory bowel disease and maintenance treatment with vedolizumab, stable for at least 4 months, were offered to switch to sc formulation.
Article Synopsis
- The study evaluates the effectiveness and safety of biological therapies for inflammatory bowel disease (IBD) in patients aged 65 and older, addressing a gap in existing research primarily focused on younger populations.
- A total of 1,090 elderly patients were included, with findings showing that a significant portion achieved clinical remission after treatment, particularly by the 52-week mark.
- Although the therapies were generally safe, there was a notable occurrence of oncological events, with variations in incidence rates depending on the specific treatment used.
A 62-year-old woman, originally from Peru, with rheumatoid arthritis under treatment with anti-tumor necrosis factor (anti-TNF) therapy, was admitted due to constitutional syndrome and suspicion of neoplasia. Computed tomography (CT) scan revealed involvement of three segments of the colon, ascites, and likely peritoneal implants. Ascitic fluid analysis showed elevated adenosine deaminase (ADA) levels and lymphocytosis.
View Article and Find Full Text PDFArticle Synopsis
- Limited data exist on the outcomes of inflammatory bowel disease (IBD) in patients who undergo solid organ transplantation (SOT), and this study examines both pre-existing IBD and newly developed IBD post-transplant.
- The study included 177 patients, of which 106 had pre-existing IBD, and found that 32% of these patients experienced disease progression after a median of 2.2 years, while 55% of those with de novo IBD progressed within 1.9 years.
- Key risk factors for progression in pre-existing IBD included having active disease at the time of SOT and extraintestinal manifestations, indicating a significant impact on patient outcomes post-transplant.*
Incidence and Course of Joint Inflammation Associated with Inflammatory Bowel Disease in Patients Undergoing Treatment with Vedolizumab/Ustekinumab: The VEDUSTAR Study.
J Clin Med
February 2024
Background: The role of ustekinumab (UST) and vedolizumab (VDZ) in the extraintestinal joint manifestations of inflammatory bowel disease (IBD) remain unclear, and most existing studies are retrospective. The aim of this prospective study was to analyze the incidence of new-onset joint disease or the worsening of pre-existing IBD-associated joint disease in patients treated with UST and VDZ.
Methods: The study population comprised IBD patients with previous spondyloarthritis (SpA) or new-onset arthropathy undergoing treatment with VDZ or UST.
Background: The rates of clinical and biochemical responses in Crohn's disease (CD) patients treated with intravenous (IV) ustekinumab (UST) intensification are scarcely described.
Methods: Patients with diagnosis of CD who were under intensified IV ustekinumab treatment (130 mg every 4 weeks) were retrospectively included, evaluating the clinical and biochemical response 12 weeks after the change in treatment regimen (switch from SC to IV), as well as the serum levels of the drug.
Results: Twenty-seven patients, all of whom had transitioned to intensified intravenous ustekinumab treatment due to a secondary loss of response to the drug, were included in the retrospective analysis.
Aim: Granulocyte and monocyte apheresis (GMA) is a potential therapeutic option when combined with various drugs for treatment of ulcerative colitis (UC). In this study, we analyze the efficacy and safety of GMA combined with vedolizumab (VDZ) during induction in patients with moderate-severe UC and incomplete response to steroids.
Patients And Methods: Single-center retrospective review of patients receiving GMA+VDZ.
It is widely acknowledged that inflammatory bowel disease (IBD) is associated with a high prevalence of sexual dysfunction (SD). However, there is a notable paucity of specific literature in this field. This lack of information impacts various aspects, including the understanding and comprehensive care of SD in the context of IBD.
View Article and Find Full Text PDFObjective: Ustekinumab was recently approved for the treatment of moderate-to-severe ulcerative colitis (UC). Although data from the UNIFI clinical trial are encouraging, real-world data assessing effectiveness and safety are scarce. The aim of this study was to assess the effectiveness, safety and pharmacokinetics of ustekinumab in a large cohort of refractory UC patients.
View Article and Find Full Text PDFIntroduction: Intestinal failure is a rare pathology which requires knowledge and highly specialized multidisciplinary management. Crohn's disease (CD) being one of the most frequent causes in adults.
Material And Methods: Survey format study carried out within the GETECCU group, included closed format questions about the diagnosis, management and current knowledge of intestinal failure in CD.
Introduction: The main clinical practice guidelines recommend endoscopy within 24hours after admission to the Emergency Department in patients with non-variceal upper gastrointestinal bleeding. However, it is a wide time frame and the role of urgent endoscopy (<6hours) is controversial.
Material And Methods: Prospective observational study carried out at La Paz University Hospital, where all patients were selected, from January 1, 2015 to April 30, 2020, who attended the Emergency Room and underwent endoscopy for suspected upper gastrointestinal bleeding.
Background And Aims: response to the SARS-CoV-2 vaccine can be altered in patients with immune-mediated diseases, such as inflammatory bowel disease, and in patients under immunosuppressive treatment. The aims of this study were to evaluate the serologic response to the SARS-CoV-2 vaccine in patients with inflammatory bowel disease, to analyze the influence of immunosuppressive drugs on response, and to describe any adverse events in this population.
Methods: this was a prospective study that included adult patients with inflammatory bowel disease.
Background: Data regarding bowel preparation in patients with Inflammatory Bowel Disease (IBD) are scarce.
Aim: To compare efficacy, safety, and tolerability of low-volume preparations in patients with IBD.
Methods: Single-center, randomized, prescriber, and colonoscopist-blinded clinical trial.
This is a case report on the colonoscopic finding of intestinal pneumatosis.
View Article and Find Full Text PDFIt is presented a case study of intestinal affectation on a patient under tocilizumab treatment for giant cell arteritis.
View Article and Find Full Text PDFArticle Synopsis
- Chronic immune-mediated diseases like IBD are linked to higher risks of early heart disease and cardiovascular events among patients.
- A study involving 374 IBD patients analyzed their cardiovascular health at the start and after one year, focusing on the impact of different biologic treatments and inflammatory activity.
- Findings showed changes in blood glucose and cholesterol levels for patients on anti-TNFα treatments, but no significant differences in cardiovascular events were observed based on the type of medication, personal history, or inflammation levels.
Background And Aims: Patients with colonic inflammatory bowel disease (IBD) have a high risk of colorectal cancer (CRC). Current guidelines recommend endoscopic surveillance, yet epidemiological studies show poor compliance. The aims of our study were to analyse adherence to endoscopic surveillance, its impact on advanced colorectal lesions, and risk factors of non-adherence.
View Article and Find Full Text PDFBackground: The impact of biologics on the risk of postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack of evidence is more relevant for ustekinumab and vedolizumab.
Aims: To evaluate the impact of biologics on the risk of PC.